Kovitz Investment Group Partners LLC Buys 3,090 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Kovitz Investment Group Partners LLC increased its stake in Regeneron Pharmaceuticals by 80.5%, owning 6,929 shares valued at $4.39 million at the end of the first quarter.
• Several institutional investors also boosted their positions in Regeneron, with GAMMA Investing LLC's stake rising dramatically by 89,825.0% to 815,620 shares worth approximately $517 million.
• Regeneron recently reported quarterly earnings of $12.89 per share, exceeding analyst estimates and showing a 3.6% revenue increase year-over-year.

Kovitz Investment Group Partners LLC boosted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 80.5% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 6,929 shares of the biopharmaceutical company's stock after purchasing an additional 3,090 shares during the period. Kovitz Investment Group Partners LLC's holdings in Regeneron Pharmaceuticals were worth $4,395,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the company. Marietta Wealth Management LLC increased its stake in Regeneron Pharmaceuticals by 30.2% in the 1st quarter. Marietta Wealth Management LLC now owns 10,778 shares of the biopharmaceutical company's stock valued at $6,836,000 after buying an additional 2,501 shares during the period. GAMMA Investing LLC boosted its holdings in Regeneron Pharmaceuticals by 89,825.0% in the 1st quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock valued at $517,291,000 after purchasing an additional 814,713 shares during the period. China Universal Asset Management Co. Ltd. boosted its holdings in Regeneron Pharmaceuticals by 3.9% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 25,629 shares of the biopharmaceutical company's stock valued at $16,255,000 after purchasing an additional 955 shares during the period. KBC Group NV boosted its holdings in Regeneron Pharmaceuticals by 9.4% in the 1st quarter. KBC Group NV now owns 149,440 shares of the biopharmaceutical company's stock valued at $94,779,000 after purchasing an additional 12,793 shares during the period. Finally, Lmcg Investments LLC boosted its holdings in Regeneron Pharmaceuticals by 231.3% in the 1st quarter. Lmcg Investments LLC now owns 14,481 shares of the biopharmaceutical company's stock valued at $9,184,000 after purchasing an additional 10,110 shares during the period. Hedge funds and other institutional investors own 83.31% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have recently commented on REGN shares. Wells Fargo & Company downgraded shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 price objective for the company. in a report on Friday, August 1st. Citigroup reaffirmed a "buy" rating and set a $650.00 price objective on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Cantor Fitzgerald assumed coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, April 22nd. They set an "overweight" rating and a $695.00 price objective for the company. Redburn Atlantic upgraded shares of Regeneron Pharmaceuticals to a "strong-buy" rating in a research report on Thursday, August 14th. Finally, JPMorgan Chase & Co. dropped their target price on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating for the company in a research report on Monday, June 9th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $829.65.

Regeneron Pharmaceuticals Trading Down 0.4%

Regeneron Pharmaceuticals stock traded down $2.13 during midday trading on Tuesday, hitting $571.78. 854,560 shares of the stock were exchanged, compared to its average volume of 979,587. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $1,211.20. The company has a fifty day simple moving average of $546.30 and a two-hundred day simple moving average of $593.44. The stock has a market capitalization of $60.60 billion, a PE ratio of 14.41, a P/E/G ratio of 1.91 and a beta of 0.33.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The company had revenue of $3,675,600 billion for the quarter, compared to the consensus estimate of $3.30 billion. During the same period last year, the company earned $11.56 earnings per share. The firm's revenue was up 3.6% compared to the same quarter last year. Equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th will be issued a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Monday, August 18th. Regeneron Pharmaceuticals's payout ratio is currently 8.87%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.